Analysis of the Utilization of Adjuvant Drugs in 11 Tertiary Hospitals of Xi’an Area during 2013-2015
10.6039/j.issn.1001-0408.2016.23.07
- VernacularTitle:西安地区11家三级医院2013－2015年辅助用药使用分析
- Author:
Haiyan LI
;
Bin HU
- Publication Type:Journal Article
- Keywords:
Adjuvant drug;
Rational drug use;
Consumption sum;
DDDs;
DDC;
ADR;
Xi’an area
- From:
China Pharmacy
2016;27(23):3188-3190,3191
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To provide reference for promoting rational drug use and formulating medication policy by health ad-ministrative department. METHODS:The utilization of top 20 adjuvant drugs in the list of consumption sum in 11 tertiary hospitals from Xi’an area during 2013-2015 was analyzed statistically in respects of total consumption sum and constituent ratio,the con-sumption sum of single type,DDDs,DDC,ADR,etc. RESULTS:The total consumption sum and the proportion of adjuvant drugs in 11 tertiary hospitals from Xi’an area increased year by year from 2013 to 2015,accounting for 8.43%,10.25% and 12.20%,respectively. 13 kinds of adjuvant drugs were included in top 20 in the list of total consumption sum from more than 3 hospitals. Deproteinised calf blood serum injection,Alprostadil injection and Danhong injection took up the first 4 places in the list of consumption sum,and Salvianolate for injection took up the first 3 place during 2014-2015. Alprostadil injection,Xueshuantong injection and Spleen peptide oral lyophilized powder took up the first 3 places in the list of DDDs. Spleen polypeptides injection, Yiqi fumai for injection and Cattle encephalon glycoside and ignotin injection took up the first 3 places in the list of DDC,and their DDC were 885.24,372.34 and 349.37 yuan. The incidence of adjuvant drugs-induced ADR increased year by year,increasing from 9.13% of 2013 to 13.49% of 2015. CONCLUSIONS:At present,adjuvant drugs become the important part of clinical drug use in Xi’an area. The consumption sum and amount is increasing rapidly. Great importance should be attached to the rational use and safety of adjuvant drugs so as to control the unreasonable increase of drug expenses.
